Arbutus Biopharma (ABUS) vs Zevra Therapeutics (ZVRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Zevra Therapeutics (ZVRA) has outperformed Arbutus Biopharma (ABUS) over the past year, gaining 8.7% versus a gain of 0.0%. Over five years, ZVRA leads with a +12.6% price change compared with +2.5% for ABUS. Zevra Therapeutics is the larger company by market cap ($653.2 million vs $640.7 million), about 1.0 times the size.
On valuation, Arbutus Biopharma trades at a lower trailing P/E (5.3x vs 12.0x for Zevra Therapeutics).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABUS | ZVRA |
|---|---|---|
| Share price | $4.18 | $11.00 |
| Market cap | $640.69M | $653.22M |
| 1-day change | -2.56% | -0.72% |
| YTD return | -13.10% | +23.66% |
| 1-year return | 0.00% | +8.73% |
| 5-year return | +2.45% | +12.59% |
| P/E ratio (TTM) | 5.29 | 11.96 |
| Forward P/E | — | 10.22 |
| EPS (TTM) | $0.79 | $0.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.45 | $15.04 |
| 52-week low | $3.50 | $8.01 |
| Distance from 52-week high | -23.30% | -26.84% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +27.99% | +127.27% |
| Average volume | 4.71M | 1.11M |
| Shares outstanding | 153.28M | 59.38M |
| Employees | 19 | 61 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Zevra Therapeutics trades at a higher earnings multiple (12.0x vs 5.3x trailing P/E).
About Arbutus Biopharma
ABUS stock →Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1.
Health Care · Biotechnology: Pharmaceutical Preparations · 19 employees
About Zevra Therapeutics
ZVRA stock →Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform.
Health Care · Biotechnology: Pharmaceutical Preparations · 61 employees
ABUS vs ZVRA FAQ
Which is bigger, Arbutus Biopharma or Zevra Therapeutics?
Zevra Therapeutics (ZVRA) is larger, with a market capitalization of $653.22M compared with $640.69M for Arbutus Biopharma (ABUS).
Which stock has performed better over the past year, ABUS or ZVRA?
ZVRA returned +8.73% over the past 12 months, compared with 0.00% for ABUS (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ABUS or ZVRA?
ABUS has the lower trailing P/E at 5.3, versus 12.0 for ZVRA. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Arbutus Biopharma and Zevra Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.